Bemdec (Bempedoic Acid) — Prescribing Guide

Brand: Bemdec (India) | NEXLETOL (USA)
Class: ATP-citrate lyase (ACL) inhibitor — reduces hepatic cholesterol synthesis upstream of HMG-CoA reductase
Dose: 180 mg orally once daily, with or without food

---

Step 1 — Confirm the Indication

Bempedoic acid is indicated as add-on to maximally tolerated statin therapy in adults who need further LDL-C lowering with either:

• Heterozygous familial hypercholesterolaemia (HeFH), OR
• Established atherosclerotic cardiovascular disease (ASCVD)

⚠️ CV morbidity/mortality benefit has not been established. It lowers LDL-C, not proven outcomes (as of 2020 label).
Not approved in children (<18 years).

---

Step 2 — Check the Current Statin for Interaction

This is the most important safety check before prescribing.

Statin	Action Required
Simvastatin >20 mg/day	Reduce to ≤20 mg or switch statin before starting Bemdec
Pravastatin >40 mg/day	Reduce to ≤40 mg or switch statin before starting Bemdec
Atorvastatin	No dose cap — safe at any approved dose
Rosuvastatin	No dose cap — safe at any approved dose

Why: Bemdec raises simvastatin AUC ~2-fold and pravastatin AUC ~2-fold → increased myopathy risk. Atorvastatin and rosuvastatin elevations are minor (~1.7-fold) and do not require dose adjustment.

---

Step 3 — Screen Special Populations Before Starting

Population	Decision
Pregnancy	Stop Bemdec unless benefit clearly outweighs fetal risk. Advise contraception.
Breastfeeding	Avoid — potential harm to infant; mechanism-based concern
Renal: mild–moderate (eGFR ≥30)	No dose adjustment needed
Renal: severe (eGFR <30) / ESRD on dialysis	Limited data — use with caution; not studied in ESRD
Hepatic: Child-Pugh A or B	No dose adjustment needed
Hepatic: Child-Pugh C	Not studied — avoid
Age ≥65	No dose adjustment — well-represented in trials (58% were ≥65)
Prior gout history	⚠️ High risk for gout flare — check uric acid before starting; consider prophylaxis
Prior tendon disorders	⚠️ Higher tendon rupture risk — discuss alternative therapy

---

Step 4 — Start and Schedule Monitoring

1. Start: 180 mg once daily with maximally tolerated statin
2. Lipid check: Recheck LDL-C at 8–12 weeks after initiation
3. Uric acid: Check at baseline and at 4 weeks (peak rise occurs in first 4 weeks)
4. LFTs / CK: Check if symptoms develop — not required routinely unless symptomatic

---

Step 5 — Monitor and Manage Adverse Effects

🔴 Hyperuricemia (Gout Risk)

• Incidence: Uric acid rises in 26% of patients; clinically significant hyperuricemia in 3.5%
• Gout: 1.5% on Bemdec vs 0.4% placebo; rises to 11.2% in those with prior gout history
• Action:
  • Asymptomatic rise: monitor periodically
  • Symptomatic gout: start urate-lowering therapy (allopurinol/febuxostat); do not stop Bemdec unless severe

🔴 Tendon Rupture

• Incidence: 0.5% vs 0% placebo — rotator cuff, biceps, Achilles most common
• Risk factors: Age >60, corticosteroids, fluoroquinolones, renal failure, prior tendon disorder
• Red flags — STOP IMMEDIATELY: snap/pop sensation, acute pain, bruising over tendon, inability to move/weight-bear
• Yellow flags — consider stopping: new joint pain, swelling, or inflammation → switch to alternative lipid-lowering therapy
• Rule: Discontinue Bemdec at first sign of tendon rupture. Avoid in patients with prior tendon rupture history.

Common Adverse Effects (≥2%, >placebo)

Effect	Bemdec	Placebo
Muscle spasms	3.6%	2.3%
Hyperuricemia	3.5%	1.1%
Back pain	3.3%	2.2%
Abdominal pain	3.1%	2.2%
Pain in extremity	3.0%	1.7%
Elevated liver enzymes	2.1%	0.8%

AST elevations >3× ULN: 1.4% vs 0.4%. Usually transient. Check LFTs if symptomatic.
Haemoglobin drop ≥2 g/dL: 5.1% — generally asymptomatic.
Platelet rise >100×10⁹/L: 10.1% — not clinically significant.

---

Step 6 — Patient Counselling Points

1. Take once daily, with or without food
2. Inform about gout risk — report severe joint pain, swelling especially in the big toe
3. Inform about tendon risk — rest immediately and call if snap/pop/pain in shoulder, upper arm, or heel
4. Alert on simvastatin/pravastatin muscle risk if co-prescribed
5. Stop and call if pregnant
6. LDL-C check at 8–12 weeks after starting

---

Clinical Guardrails

• Do not use as monotherapy — must be adjunct to maximally tolerated statin
• Do not combine with simvastatin >20 mg or pravastatin >40 mg
• Do not start in Child-Pugh C or ESRD — no safety data
• Do not ignore new musculoskeletal complaints — could be tendon warning
• Bempedoic acid does not interact with warfarin, metformin, or oral contraceptives

---

Source: NEXLETOL (bempedoic acid) FDA Prescribing Information. Esperion Therapeutics, Inc. Reference ID: 4564667. Revised: 02/2020. https://www.fda.gov/drugsatfda